Docosahexaenoic Acid

We are Docosahexaenoic Acid CAS:6217-54-5 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name: Docosahexaenoic Acid
Synonyms:DHA
Doconexent
22:6(n-3) fatty acid
docosahexenoic acid
Cervonic acid
 
CAS.NO: 6217-54-5
Molecular Formula: C22H32O2
Molecular Weight: 328.48800
 
Physical and Chemical Properties:
Density: 0.943 g / cm3
Boiling point: 446.7ºC at 760 mmHg
Melting point: -44ºC
Flash point: 62ºC
Refractive index: 1.521
 
Specification:
Appearance:Light yellow to yellow transparent liquid
Purity:≥99%
 
Packing:1kg / 5KG / aluminum bottle, filled with nitrogen
Storage:Sealed and protected from light and filled with nitrogen. Store in a cool, dark place. Take care to prevent its oxidative deterioration.
Application:Suitable for food, pet nutrition, cosmetics and pharmaceutical industries

Docosahexaenoic Acid


Related News: DMF is the main management method for APIs in developed countries in Europe and the United States. Under the DMF system, API companies can submit DMF filing documents to the regulatory authority at any time, but the regulatory authority will not conduct technical reviews on them. When the drug is administered, the regulatory authority will associate and review the drug substance and the preparation.4461-34-1 At the same time, through years of imitation and advanced technology learning, more and more domestic companies have participated in the field of highly original and characteristic APIs.5-Fluoronicotinic acid Many branded versions of drugs are currently more expensive in China than in other major markets. They could now be subjected to a centralized procurement program where manufacturers will have to go through a bidding process to get the right to supply drugs to public hospitals, the National Health Commission said in a document published on late Friday.1591-31-7 The Company’s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs).The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study.

Related Products
Product Name
5-(Trifluoromethyl)pyridine-2-carboxylic acid View Details
N-(m-tolyl)dibenzo[b,d]furan-4-amine View Details
1-Hydroxybenzotriazole Hydrate View Details
4-Amino-6-(2-methyl-2-propanyl)-3-thioxo-3,4-dihydro-1,2,4-triazi n-5(2H)-one manufacturer 1-CYCLOPROPYL-6,7-DIFLUORO-1,4-DIHYDRO-4-OXOQUINOLINE-3-CARBOXYLIC ACID manufacturer Fmoc-L-Trp(Boc) manufacturer 4-Fluorobenzotrifluoride manufacturer HC Yellow 7 manufacturer